Evidence map›Paper›PMID 36678692›Full record

ArticlePharmaceutics2022

Lactobacilli as a Vector for Delivery of Nanobodies against Norovirus Infection.

Yoshikazu Yuki, Fanglei Zuo, Shiho Kurokawa, Yohei Uchida, Shintaro Sato, Naomi Sakon, Lennart Hammarström, Hiroshi Kiyono, Harold Marcotte

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Nanobodies in animal infectious disease control: diagnosis and therapy.Frontiers in cellular and infection microbiology · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Yoshikazu YukiDivision of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Fanglei ZuoDepartment of Biosciences and Nutrition, Karolinska Institutet, SE-141 83 Huddinge, Sweden.ORCID 0000-0002-4545-1265
Shiho KurokawaDivision of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Yohei UchidaDivision of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Shintaro SatoDepartment of Microbiology and Immunology, School of Pharmaceutical Sciences, Wakayama Medical University, Wakayama 641-0011, Japan.
Naomi SakonDepartment of Microbiology, Osaka Institute of Public Health, Osaka 537-0025, Japan.
Lennart HammarströmDepartment of Biosciences and Nutrition, Karolinska Institutet, SE-141 83 Huddinge, Sweden.
Hiroshi KiyonoDivision of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Harold MarcotteDepartment of Biosciences and Nutrition, Karolinska Institutet, SE-141 83 Huddinge, Sweden.ORCID 0000-0002-7168-349X
Chiba University Hospital · JPKarolinska Institutet · SEChiba University · JPOsaka Prefectural Institute of Public Health · JPWakayama Medical University · JP

Funding

GAP fund program under The University of Tokyo Not applicablethe Japan Agency for Medical Research and Development JP20fk0108122
6 · The paper itself

Abstract

Passive administration of neutralizing antibodies (Abs) is an attractive strategy for the control of gastrointestinal infections. However, an unanswered practical concern is the need to assure the stability of sufficient amounts of orally administered neutralizing Abs against intestinal pathogens (e.g., norovirus) in the harsh environment of the gastrointestinal tract. To this end, we expressed a single-domain Ab (VHH, nanobody) against norovirus on the cell surface of

Indexed as

Lactobacillusnanobodynorovirussingle-domain antibody

Identifiers

PMID36678692
PMCPMC9863548
OpenAlexW4313244289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.